Prostate Cancer Diagnostics Market to Raise over $10 Billion by 2024 at a CAGR of Around 7.5%

Description :

Global QYResearch in its latest report on “Global Prostate Cancer Diagnostics Market (Types: Tumor Biomarker Tests, Imaging, Biopsy, Other; Application: < 55, 55-75, > 75)”, estimate that global market for prostate cancer diagnostics is predictable to grow at a substantial rate of around 7.5% CAGR and increase the market over $10 Billion by 2024. One of the central point increasing the interest in the worldwide prostate cancer diagnostics market is constant technological advancement. On the other hand, expanding rate of prostate cancer is raising the level of interest in the market.
Enhancing alertness advanced cancer diagnostics technologies in emerging economies and various government activities undertaken to support it are anticipated to drive the development of the worldwide prostate cancer diagnostics market in near future. Popularity for prostate malignant growth diagnostics in developing nations, for example, China and Japan is reinforcing the market. Moreover, the accessibility of advanced human services infrastructure in North America is predicted to boost the development to the prostate cancer diagnostics market.
Download Sample copy of this report@
Segment Outlook
On the basis of end user, the global prostate cancer diagnostics market sees a classification into >75 years, 55-75 years, and <55 years. Analysis shows that, end users aged between 55 and 75 years considerably amplified the demand in the global prostate cancer diagnostics market. In 2017, this segmented accounted around 69.0% share of the total market. By product, tumor biomarker tests bagged over 59% share of the overall market. On the other hand, the biopsy method is typically used for prostate cancer diagnostics.
View Detail Report With Complete Table of Content, List of Table and Figure@
North America Held Most Astounding Piece in The Overall Market 
The Prostate Cancer Diagnostics consumption is quickly expanding in North America. Advancement in technology and various innovations in medical sectors are key contributors to the growth. In 2017, the region secured a consumption share of over 47% in terms of value. In the same year, Europe treaded upon the heels of North America, collecting over 28% consumption share of the market.
Key Players
OPKO, Siemens Healthcare, Genomic Health, and Abbott are several leading companies of global prostate cancer diagnostics market. These players have held strong positions in the market as they deal with premier customers and seize vital technologies and patents. Also, bioMeriux, Roche, MDx Health, DiaSorin, Myriad Genetics, Ambry Genetics are profiled in this report.
The report is readily available and can be dispatched within 4hr after payment confirmation.
Buy this premium research report -
Would like to place an order or any question, please feel free to contact at | +44 20 3286 1546


Copyright © 2019 Global QYResearch